Indicators of amyloid burden in a population-based study of cognitively normal elderly (Q36330933)

13 August 2017

Indicators of amyloid burden in a population-based study of cognitively normal elderly (English)

1 reference

13 August 2017

13

1 reference

13 August 2017

Michelle M Mielke

1

0 references

Ronald C. Petersen

series ordinal

12

object named as

Ronald C Petersen

1 reference

13 August 2017

4

David S Knopman

1 reference

13 August 2017

9

Bradley F Boeve

1 reference

13 August 2017

5

Val J Lowe

1 reference

13 August 2017

10

Matthew L Senjem

1 reference

13 August 2017

11

Prashanthi Vemuri

1 reference

13 August 2017

2

Heather J Wiste

1 reference

13 August 2017

3

Stephen D Weigand

1 reference

13 August 2017

6

Rosebud O Roberts

1 reference

13 August 2017

7

Yonas E Geda

1 reference

PMCID

3475629

13 August 2017

Dana M Swenson-Dravis

series ordinal

8

object named as

Dana M Swenson-Dravis

1 reference

PMCID

3475629

13 August 2017

language of work or name

English

0 references

publication date

12 September 2012

1 reference

13 August 2017

1 reference

13 August 2017

79

1 reference

13 August 2017

1570-1577

1 reference

13 August 2017

15

1 reference

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

APOE modifies the association between Aβ load and cognition in cognitively normal older adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Testing the right target and right drug at the right stage

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Clinical trial methodologies for disease-modifying therapeutic approaches

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Resolving controversies on the path to Alzheimer's therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Amyloid-dependent and amyloid-independent stages of Alzheimer disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Amyloid deposition is associated with impaired default network function in older persons without dementia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Frequent amyloid deposition without significant cognitive impairment among the elderly

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Neuropathological stageing of Alzheimer-related changes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3475629

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22972644

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0B013E31826E2696

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

PMCID

3475629